The correct administration of Dymista® will lead to optimum efficacy, thereby increasing patient compliance
Click below for further information on the correct administration technique, discussed by leading Key Opinion Leaders in Allergic Rhinitis
Further Your Understanding
Click on one of the below links to discover more information about Dymista®, including Flow to use Dymista®, guidelines, clinical papers and request materials.
Impact of Rhinitis
- Price D Bousquet J. Bachert C el al. MP29.o2 a novel intranasal therapy for the treatment of chronic rhinitis: safety data from a 12 month trial. Presented at EEAACI Geneva 16-21 June 2013. Patients were chronic AR patients treated over 12 months at the recommended dosages. Dymista® (n=404). FP (n=207)